Evidence map›Paper›PMID 30334877›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.

Joel Milam, Sonia Jain, Michael P Dubé, Eric S Daar, Xiaoying Sun, Katya Corado, Eric Ellorin, Jill Blumenthal, Richard Haubrich, David J Moore and 2 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Questioning risk compensation: pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joel MilamKeck School of Medicine, University of Southern California, Los Angeles, CA.
Sonia JainUniversity of California, San Diego, San Diego, CA.
Michael P DubéKeck School of Medicine, University of Southern California, Los Angeles, CA.
Eric S DaarLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
Xiaoying SunUniversity of California, San Diego, San Diego, CA.
Katya CoradoLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
Eric EllorinUniversity of California, San Diego, San Diego, CA.
Jill BlumenthalUniversity of California, San Diego, San Diego, CA.
Richard HaubrichGilead Sciences Inc, Foster City, CA.
David J MooreUniversity of California, San Diego, San Diego, CA.
Sheldon R MorrisUniversity of California, San Diego, San Diego, CA.
CCTG Team

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
Improving Antiretroviral Management for HIVK24AI064086 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAUBRICH, RICHARD H · 2006 to 2015
$1.8M
Risk compensation and pre-exposure prophylaxis use to prevent HIV infection--supplementR21MH100979 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E, MORRIS, SHELDON ROBERT · 2013 to 2015
$544k
NIAID NIH HHS K24 AI064086NIAID NIH HHS P30 AI036214NIMH NIH HHS P30 MH062512NIMH NIH HHS R21 MH100979
6 · The paper itself

Abstract

backgroundA public health concern regarding HIV pre-exposure prophylaxis (PrEP) is sexual risk compensation (ie, increased unsafe sex among PrEP users that may undermine prevention efforts).

methodsThis demonstration study (NCT#01761643; initiated in 2013) included 398 men who have sex with men who initiated PrEP and were followed over 48 weeks at 4 sites in Southern California. Wilcoxon signed-rank tests compared previous 30-day number of sex partners and condomless insertive anal sex and receptive anal sex (CIAS and CRAS, respectively) acts at weeks 4, 12, 24, 36, and 48 to baseline. At 2 sites, PrEP users were also compared with a lagged, comparison group of 99 men who have sex with men who did not receive PrEP over 24 weeks using linear regression models, adjusting for age, race/ethnicity, education, and respective baseline scores. Logistic regression compared week 24 sexually transmitted infection (STI) rates.

resultsOver 48 weeks in the PrEP group, there were significant decreases in the number of unknown HIV status sex partners and increases in CRAS at all study visits; there was no consistent change in number of HIV+ sex partners or CIAS. Among participants at 2 sites, there were no significant differences between PrEP and non-PrEP users in change in number of partners, CIAS, CRAS, or STI rates at week 24.

conclusionsAmong early adopters of PrEP, there is some evidence for sexual risk compensation. Results support current guidelines of regular STI screening and behavioral risk reduction and adherence counseling with the provision of PrEP.

Indexed as

Pre-Exposure ProphylaxisAdultAnti-HIV AgentsDirective CounselingFemaleHealth SurveysHIV InfectionsHomosexuality, MaleHumansMaleModels, TheoreticalTenofovirTransgender PersonsUnsafe SexAnti-HIV AgentsTenofovir

Identifiers

PMID30334877
PMCPMC6289757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.